Evidence map›Paper›PMID 36159831›Full record

ArticleFrontiers in immunology2022

Prognostic stratification based on m

Ping Liu, Ziqing Zhu, Jiayao Ma, Le Wei, Ying Han, Edward Shen, Xiao Tan, Yihong Chen, Changjing Cai, Cao Guo and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Ping LiuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Ziqing ZhuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Jiayao MaDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Le WeiDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Ying HanDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Edward ShenDepartment of Life Science, McMaster University, Hamilton, ON, Canada.
Xiao TanDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Yihong ChenDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Changjing CaiDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Cao GuoDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Yinghui PengDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Yan GaoDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Yongting LiuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Qiaoqiao HuangDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Le GaoDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Yin LiDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Zhaohui JiangDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Wantao WuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Yihan LiuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Shan ZengDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Wei LiDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Ziyang FengDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Hong ShenDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immunotherapy is a promising anti-cancer strategy in hepatocellular carcinoma (HCC). However, a limited number of patients can benefit from it. There are currently no reliable biomarkers available to find the potential beneficiaries. Methylcytosine (m Methods: In this study, we analyzed 371 HCC patients from The Cancer Genome Atlas (TCGA) database and investigated the expression of 18 m Results: The 1-, 3-, and 5-year area under the curve (AUC) of m Conclusion: In conclusion, our study helps to early screen HCC patients and select patients who can benefit from immunotherapy. Step forwardly, for the less likely beneficiaries, this study provides them with new potential targeted drugs and agents for choice to improve their prognosis.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAxitinibBiomarkers, TumorDocetaxelGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunotherapyPrognosisVinblastineAxitinibBiomarkers, TumorDocetaxelVinblastinebiomarkerdrug sensitivityHCCimmunotherapym5Cprecision medicine

Identifiers

PMID36159831
PMCPMC9505913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.